Resource Type

Journal Article 1

Year

2022 1

Keywords

cabozantinib 1

hepatocellular carcinoma 1

primary resistance 1

rapamycin 1

Search scope:

排序： Display mode:

Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 467-482 doi: 10.1007/s11684-021-0869-y

Abstract: Cabozantinib, mainly targeting cMet and vascular endothelial growth factor receptor 2, is the second-lineMechanically, the combination of rapamycin with cabozantinib resulted in the remarkable inhibition ofMeanwhile, rapamycin enhanced the inhibitory effects of cabozantinib on the migration and tubule formationIn conclusion, our findings uncover a potential combination therapy of cabozantinib and rapamycin tocombat cabozantinib-resistant HCC.

Keywords： hepatocellular carcinoma     cabozantinib     primary resistance     rapamycin    

HTML PDF Collect

Title Author Date Type Operation

Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular

Journal Article